Aptus Pharma board approves ₹51 cr fund raise for expansion
The nano-cap pharma plans to raise ₹35 cr via preferential equity, ₹10 cr debt, and ₹6 cr internal accruals. The preferential allotment is subject to approvals with pricing and allottees yet to be decided.
— 1 earlier story on Aptus Pharma Ltd. →What's new
- Aptus Pharma board approved fund raising up to ₹51 cr.
- ₹35 cr via preferential allotment, ₹10 cr debt, ₹6 cr internal accruals.
- Preferential allotment details pending; managing director authorized to negotiate.
Why this matters
For a ₹371 cr market cap company with quarterly sales of ₹32 cr, raising ₹51 cr is material. The ₹35 cr equity component alone implies over 9% dilution for existing shareholders. If executed, it strengthens the balance sheet but leaves unanswered questions on pricing and investor quality.
What we're watching
- Identity and pricing of allottees in the preferential allotment.
- Shareholder and regulatory approval timeline.
- Impact on the debt/equity ratio of 1.49.
The full read
Aptus Pharma, a nano-cap pharma with a ₹371 cr market cap and ₹32 cr quarterly sales, has approved a ₹51 cr fund raise—₹35 cr via preferential equity, ₹10 cr debt, and ₹6 cr internal accruals. The equity component alone could dilute existing holders by over 9%. But the board resolution is enabling: pricing and allottee identities remain unspecified. Managing director Tejas Hathi will handle investor negotiations. The company's trailing P/E of 80x and ROE of 44.5% point to high profitability, though a debt/equity of 1.49 shows past debt use. The capital, if raised, would fund expansion. For now, the market has a concrete number it didn't have before the board meeting. The real test lies in the terms yet to be disclosed.
Questions answered
- How much is Aptus Pharma raising and why?
- The board approved a fund raise of up to ₹51 cr to expand business operations. The breakdown: ₹35 cr preferential equity, ₹10 cr debt, ₹6 cr internal accruals.
- What is the breakdown of the ₹51 crore?
- ₹35 crore via preferential allotment of securities, ₹10 crore through debt financing, and ₹6 crore from internal accruals.
- Is the fund raising final?
- No, it is an enabling board resolution. The preferential allotment is subject to shareholder and regulatory approvals. Pricing and allottee identities are yet to be finalized.
- What does this mean for existing shareholders?
- The ₹35 cr equity component alone implies a dilution of over 9% for current holders, which is material for a nano-cap company.
- When will details of the preferential allotment be known?
- The board has delegated authority to managing director Tejas Hathi to identify and negotiate with prospective investors. No timeline has been provided.
Aptus Pharma Ltd.
Latest quarter · Mar 2026
Strength & growth
Story so far
All notes on APPL →- 12 Jun 2026 · 5:47 PM IST Aptus Pharma board approves ₹51 cr fund raise for expansion
- 3d ago Aptus Pharma's board meets next week to figure out how to raise money